MAPT and Alzheimer disease: Studies suggest that physiological modifications in the cerebral vasculature may contribute to AD pathology and cognitive decline prior to clinically detectable changes in amyloid beta (Aβ) and tau, diagnostic biomarkers of AD (Sweeney et al., 2018, 2019).